Skip to main content
. 2022 May 16;132(10):e157707. doi: 10.1172/JCI157707

Figure 2. Flow of the UB-612 phase II study and characteristics of study participants.

Figure 2

(A and B) The phase II trial (NCT04773067) was conducted between February 26, 2021 and April 16, 2021, and enrolled a total of 3,875 participants (18–85 years old) to receive 100 μg UB-612 (3,321 on 100 μg UB-612 and 554 on placebo at a 6:1 ratio).